Aldeyra Therapeutics presents at Oppenheimer Healthcare Conference; no material new financial data disclosed

Aldeyra Therapeutics, Inc.

CEO Todd Brady participates virtually in fireside chat at Oppenheimer 34th Annual Healthcare Life Sciences Conference on Feb 13, 2024.
Discussion covers clinical and regulatory status of Aldeyra's product candidates for immune-mediated diseases.
Corporate presentation furnished as Exhibit 99.1; no earnings or financial guidance provided.
Filing is Regulation FD disclosure; presentation not incorporated by reference.
No specific milestones, data readouts, or financial results announced in the exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.